SKINBIOTHERAPEUTICS PLC |
Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
| 9 GBX | -2.70% |
|
-7.69% | -40.98% |
| Apr. 05 | SkinBioTherapeutics Gets Bond Conversion Notice from Macquarie | MT |
| Mar. 22 | SkinBioTherapeutics half-year revenue jumps on UK-based sales | AN |
| Sales 2024 * | 1.1M 1.37M | Sales 2025 * | - | Capitalization | 17.83M 22.28M |
|---|---|---|---|---|---|
| Net income 2024 * | -2M -2.5M | Net income 2025 * | - | EV / Sales 2024 * | 16.8 x |
| Net Debt 2024 * | 600K 750K | Net cash position 2025 * | - 0 | EV / Sales 2025 * | - |
| P/E ratio 2024 * |
-6.17
x | P/E ratio 2025 * |
-
| Employees | 11 |
| Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 72.98% |
More Fundamentals
* Assessed data
More news
More press releases
| 1 day | -2.70% | ||
| 1 week | -7.69% | ||
| Current month | -29.41% | ||
| 1 month | +5.88% | ||
| 3 months | -29.41% | ||
| 6 months | -66.67% | ||
| Current year | -40.98% |
1 week
9.00
10.00
1 month
8.5014.20
Current year
7.0018.50
1 year
7.0029.50
3 years
7.0088.00
5 years
5.0088.00
10 years
5.0088.00
| Managers | Title | Age | Since |
|---|---|---|---|
Stuart Ashman
CEO | Chief Executive Officer | - | 19-04-17 |
Manprit Randhawa
DFI | Director of Finance/CFO | 41 | 22-05-31 |
Stephen France
COO | Chief Operating Officer | - | - |
| Members of the board | Title | Age | Since |
|---|---|---|---|
| Director/Board Member | - | 17-02-28 | |
Martin Hunt
CHM | Chairman | 66 | 16-10-02 |
Stuart Ashman
CEO | Chief Executive Officer | - | 19-04-17 |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-04-25 | 9 | -2.70% | 59 888 |
| 24-04-24 | 9.25 | 0.00% | 230,111 |
| 24-04-23 | 9.25 | 0.00% | 186,038 |
| 24-04-22 | 9.25 | 0.00% | 30,151 |
| 24-04-19 | 9.25 | -5.13% | 58,268 |
Delayed Quote London S.E., April 25, 2024 at 10:16 am EDT
More quotes
SkinBioTherapeutics plc is a United Kingdom-based life science company, which is focused on skin health. The principal activity of the Company is that of research and development focused on harnessing the microbiome for human health. The Companyâs segments include UK, US, and EU. The Company's platform technology, SkinBiotix, applies research discoveries made on the activities of lysates derived from probiotic bacteria when applied to skin. The Company is targeting five specific skin healthcare sectors, such as cosmetics skincare, food supplements for the treatment of skin conditions, medical skin care, infection control in both the home and the hospital environment, and pharmaceuticals for the prescribed treatment of skin conditions. The Company's product, AxisBiotix-Ps, is a food supplement to address the symptoms of mild to moderate psoriasis. The Company is also focused on the application of SkinBiotix technology in the treatment of various classes of skin wounds.
Calendar
2024-11-25
- Q4 2024 Earnings Release (Projected)
EPS Revisions
Annual profits - Rate of surprise
| 1st Jan change | Capi. | |
|---|---|---|
| -40.98% | 22.17M | |
| -3.06% | 104B | |
| +1.06% | 97.42B | |
| +0.79% | 22.2B | |
| -18.07% | 21.23B | |
| -11.11% | 18.33B | |
| -42.83% | 16.35B | |
| -16.33% | 15.06B | |
| +4.16% | 13.98B | |
| +30.70% | 11.66B |
- Stock Market
- Equities
- SBTX Stock
